570 related articles for article (PubMed ID: 17353864)
41. [Medical preservation of ovarian function before and during radiochemotherapy].
Fénichel P
Gynecol Obstet Fertil; 2005 Sep; 33(9):610-4. PubMed ID: 16126441
[TBL] [Abstract][Full Text] [Related]
42. Reproduction after breast cancer.
Zervoudis S; Iatrakis G; Navrozoglou I
Best Pract Res Clin Obstet Gynaecol; 2010 Feb; 24(1):81-6. PubMed ID: 20170848
[TBL] [Abstract][Full Text] [Related]
43. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents.
Elizur SE; Chian RC; Pineau CA; Son WY; Holzer HE; Huang JY; Gidoni Y; Levin D; Demirtas E; Tan SL
Rheumatology (Oxford); 2008 Oct; 47(10):1506-9. PubMed ID: 18660508
[TBL] [Abstract][Full Text] [Related]
44. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist.
Ozcelik B; Turkyilmaz C; Ozgun MT; Serin IS; Batukan C; Ozdamar S; Ozturk A
Fertil Steril; 2010 Mar; 93(5):1609-14. PubMed ID: 19339002
[TBL] [Abstract][Full Text] [Related]
45. [Female fertility preservation in autoimmune diseases: possibilities and practises in France].
Carré-Pigeon F; Schubert B
Gynecol Obstet Fertil; 2007 Sep; 35(9):853-60. PubMed ID: 17707674
[TBL] [Abstract][Full Text] [Related]
46. Protective effect of dienogest on chemotherapy-induced reduced fertility in female rats.
Tsuyoshi H; Orisaka M; Fukuda S; Hattori K; Tsang BK; Yoshida Y
Steroids; 2015 Jan; 93():1-7. PubMed ID: 25449767
[TBL] [Abstract][Full Text] [Related]
47. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
[TBL] [Abstract][Full Text] [Related]
48. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
[TBL] [Abstract][Full Text] [Related]
49. Ovarian tissue cryopreservation and transplantation in cancer patients.
Donnez J; Jadoul P; Squifflet J; Van Langendonckt A; Donnez O; Van Eyck AS; Marinescu C; Dolmans MM
Best Pract Res Clin Obstet Gynaecol; 2010 Feb; 24(1):87-100. PubMed ID: 19850531
[TBL] [Abstract][Full Text] [Related]
50. Ovarian function and childbearing issues in breast cancer survivors.
Gadducci A; Cosio S; Genazzani AR
Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162
[TBL] [Abstract][Full Text] [Related]
51. Pregnancy and assisted reproduction techniques in men and women after cancer treatment.
Gurgan T; Salman C; Demirol A
Placenta; 2008 Oct; 29 Suppl B():152-9. PubMed ID: 18790328
[TBL] [Abstract][Full Text] [Related]
52. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice.
Meirow D; Assad G; Dor J; Rabinovici J
Hum Reprod; 2004 Jun; 19(6):1294-9. PubMed ID: 15117898
[TBL] [Abstract][Full Text] [Related]
53. Fertility preservation after chemotherapy for Hodgkin lymphoma.
van der Kaaij MA; van Echten-Arends J; Simons AH; Kluin-Nelemans HC
Hematol Oncol; 2010 Dec; 28(4):168-79. PubMed ID: 20232475
[TBL] [Abstract][Full Text] [Related]
54. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
[TBL] [Abstract][Full Text] [Related]
55. Fertility preservation: a comprehensive approach to the young woman with cancer.
Roberts JE; Oktay K
J Natl Cancer Inst Monogr; 2005; (34):57-9. PubMed ID: 15784825
[TBL] [Abstract][Full Text] [Related]
56. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate.
Meirow D; Rabinovici J; Katz D; Or R; Shufaro Y; Ben-Yehuda D
Cancer; 2006 Oct; 107(7):1634-41. PubMed ID: 16944540
[TBL] [Abstract][Full Text] [Related]
57. Depot GnRH-agonist trigger for breast-cancer patient undergoing ovarian stimulation resulted in mature oocytes for cryopreservation: a case report.
Cavagna M; Dzik A
Reprod Biomed Online; 2011 Mar; 22(3):317-9. PubMed ID: 21273128
[TBL] [Abstract][Full Text] [Related]
58. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial.
Elgindy EA; El-Haieg DO; Khorshid OM; Ismail EI; Abdelgawad M; Sallam HN; Abou-Setta AM
Obstet Gynecol; 2013 Jan; 121(1):78-86. PubMed ID: 23262931
[TBL] [Abstract][Full Text] [Related]
59. Absence of testicular protection by a gonadotropin-releasing hormone analogue against cyclophosphamide-induced testicular cytotoxicity in the mouse.
da Cunha MF; Meistrich ML; Nader S
Cancer Res; 1987 Feb; 47(4):1093-7. PubMed ID: 3542201
[TBL] [Abstract][Full Text] [Related]
60. Fertility preservation in cancer patients.
Dittrich R; Maltaris T; Hoffmann I; Oppelt PG; Beckmann MW; Mueller A
Minerva Ginecol; 2010 Feb; 62(1):63-80. PubMed ID: 20186115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
